Overview
Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-12-01
2022-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a randomized, double-blind, crossover study in healthy adult subjects. Each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. All subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Clinical Hospital Center ZemunTreatments:
Bisoprolol
Nebivolol
Criteria
Inclusion Criteria:1. Healthy subjects (male and female)
2. Age interval: 20-60 years old (inclusive)
Exclusion Criteria:
1. Any known absolute or relative contraindication to beta-blocker therapy
2. Poor echogenicity
3. A resting heart rate <60 bpm
4. A resting blood pressure < 110/70 mmHg